Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843085 | 0.78 | TGFBR1 (0.39) | APEX1TGFBR1LMNAERBB2PTGES | |
| SCHEMBL3841207 | 0.73 | NR1I2 (0.41) | TGFBR1LMNAERBB2PTGESTYMS | |
| SCHEMBL9257716 | 0.66 | HSD11B1 (0.43) | APEX1LMNAALDH1A1S100A4 | |
| SCHEMBL3838487 | 0.66 | PDE4D (0.36) | TGFBR1CYP3A4 | |
| SCHEMBL6763833 | 0.66 | MAPK1 (0.39) | LMNAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1690351 | 0.64 | HDAC3 (0.42) | LMNAALDH1A1CYP3A4 | |
| SCHEMBL25003236 | 0.64 | PARP1 (0.42) | LMNAALDH1A1CYP1A2PARP1F7 | |
| SCHEMBL25003400 | 0.64 | PARP1 (0.45) | LMNAALDH1A1CYP1A2PARP1F7 | |
| SCHEMBL2127201 | 0.64 | TGFBR1 (0.42) | APEX1TGFBR1PTGESCYP1A2CYP3A4 | |
| SCHEMBL3317224 | 0.62 | ALDH1A1 (0.50) | ALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| EP-2097084-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | Tibotec Pharmaceuticals Ltd. (IE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| EP-1549316-A4 | INHIBITORS OF TFGbeta | SCIOS INC (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | SCIOS INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006105222-A2 | CARBOXAMIDE INHIBITORS OF TGFB | SCIOS INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1549316-A1 | INHIBITORS OF TFG&bgr; | SCIOS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040132730-A1 | Inhibitors of TGFbeta | SCIOS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | APEX1 4202/4885TGFBR1 3765/4885LMNA 4285/4885 |
| US-20040132730-A1 | Inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | APEX1 4125/4885TGFBR1 1/4885LMNA 3045/4885 |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | APEX1 4746/4885TGFBR1 1/4885LMNA 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.